Genetic Predisposition to Breast & Ovarian Cancer: Prospective Study of

Clinical Trial Description

Cohort of subjects carrying a BRCA gene mutation: genetic predispositions to breast and ovarian cancers ;

Study Design

See also
Status	Clinical Trial	Phase
Completed	`NCT01291420` - Dendritic Cell Vaccination for Patients With Solid Tumors	Phase 1/Phase 2
Completed	`NCT00248911` - The Effect Of Meditation On Quality Of Life In Women With Breast Cancer And Other Gynecological Cancers	N/A
Completed	`NCT00721903` - Three Dimensional (3D) Ultrasound in Predicting Response to Breast Cancer Therapies	N/A

See also

Status

Clinical Trial

Phase

Completed

NCT01291420 - Dendritic Cell Vaccination for Patients With Solid Tumors

Phase 1/Phase 2

Completed

NCT00248911 - The Effect Of Meditation On Quality Of Life In Women With Breast Cancer And Other Gynecological Cancers

N/A

Completed

NCT00721903 - Three Dimensional (3D) Ultrasound in Predicting Response to Breast Cancer Therapies

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03667417
Study type	Observational
Source	Institut Paoli-Calmettes
Contact	Dominique GENRE, MD
Phone	33 491 22 37 78
Email	DRCI.UP@ipc.unicancer.fr
Status	Recruiting
Phase
Start date	October 15, 1999
Completion date	October 15, 2028

Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation — GENEPSO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms